|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT02173873 |
|
Date of registration:
|
14/06/2014 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I
ZIV |
|
Scientific title:
|
Ziv-aflibercept in Eyes With Eyes With Retinal Diseases and Poor Vision-phase I |
|
Date of first enrolment:
|
June 2014 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT02173873 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
Phase:
|
Phase 1
|
|
|
Countries of recruitment
|
|
Lebanon
| | | | | | | |
|
Contacts
|
|
Name:
|
Ahmad Mansour, MD |
|
Address:
|
|
|
Telephone:
|
9613377633 |
|
Email:
|
ammansourmd@gmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Ahmad Mansour, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
RHUH |
|
|
Name:
|
Ahmad Mansour, MD |
|
Address:
|
|
|
Telephone:
|
9613377633 |
|
Email:
|
ammansourmd@gmail.com |
|
Affiliation:
|
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria: Eyes with wet age related macular degeneration, central retinal vein
occlusion or diseases that require antiVEGF especially in poor vision eyes -
Exclusion Criteria: eyes that had recent eye surgery, inability to sign consent,
blepharitis, conjunctivitis
-
Age minimum:
16 Years
Age maximum:
95 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Age Related Macular Degeneration
|
|
Central Retinal Vein Occlusion
|
|
Intervention(s)
|
|
Drug: ziv-aflibercept drug
|
|
Primary Outcome(s)
|
|
OCT retinal structure
[Time Frame: 2 years]
|
|
Ziv-aflibercept in retinal diseases with poor vision: Safety monitoring by OCT and visual acuity
[Time Frame: 2 years]
|
|
Secondary ID(s)
|
|
INV 2014-194
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|